TDC
TTOO

Thompson Davis & Co’s T2 Biosystems, Inc TTOO Stock Holding History

Thompson Davis & Co’s Portfolio TTOO Stock Details TTOO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$247K Buy
7
+4
+133% +$132K 0.54% 46
2018
Q2 		$127K Buy
+3
New +$114K 0.3% 82

Other funds holding TTOO

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thompson Davis & Co's TTOO Position: Q3 2018 in Review

Thompson Davis & Co increased its T2 Biosystems, Inc (TTOO) stake by 133% in Q3 2018, buying an estimated $132K and bringing the position to 7 shares worth $247K. The position accounts for 0.54% of the portfolio, ranked #46.

Thompson Davis & Co first reported a position in TTOO in Q2 2018 and has held it in 2 quarters since. 85 funds tracked by Wall St. Rank hold TTOO as of Q3 2018.

  • Thompson Davis & Co held 7 shares of T2 Biosystems, Inc worth $247K as of Q3 2018.
  • Thompson Davis & Co bought 4 T2 Biosystems, Inc shares in Q3 2018, an estimated $132K.
  • T2 Biosystems, Inc made up 0.54% of Thompson Davis & Co's portfolio in Q3 2018, its #46 holding.
  • Thompson Davis & Co first reported a position in T2 Biosystems, Inc in Q2 2018 and has held it in 2 quarters since.
  • 85 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.